Glioblastoma multiforme (GBM) is
the deadliest brain cancer. The National Foundation for Cancer Research (NFCR) congratulated Dr. Web Cavenee and Dr. Paul B. Fisher on their discovery
of a new pharmacological agent to treat glioblastoma multiforme which they have been developing together
with NFCR support.
This new pharmacological agent could - with additional chemistry -
lead to a new drug to prevent radiation-induced invasion of GBM cells.
The researchers have tested their pharmacological agent in combination
with radiation with profound survival benefits in pre-clinical models.
‘The newly developed pharmacological agent could - with additional chemistry - lead to a new drug to prevent radiation-induced invasion of glioblastoma multiforme cells.’
Paul B. Fisher, Director of the Virginia Commonwealth
University's (VCU) Institute of Molecular Medicine (VIMM), focuses on
cancer genetics and Web Cavenee, Director of the Ludwig Institute
for Cancer Research at the University of California at San Diego focuses
An exciting breakthrough for the treatment of GBM, this is
about collaboration between two scientists on opposite coasts and shows
how NFCR research may lead to tangible therapies for multiple cancers.
NFCR has been funding Dr. Fisher's research since 2008, and Dr.
Cavenee's research starting in 2002.
"NFCR scientists are making headway
in the fight against one of the most aggressive form of cancer, GBM, by
working together on vital pre-clinical models," said Franklin C.
Salisbury, Jr., NFCR CEO. "For years, discoveries from NFCR-funded
research have led to better treatments today - and this latest discovery
by two incredibly talented scientists gives us proof there will be
improved therapies for GBM and multiple cancers in the foreseeable